OTCMKTS:TEAR TearLab (TEAR) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free TEAR Stock Alerts $0.06 0.00 (-1.86%) (As of 07/9/2020) Add Compare Share Share Today's Range$0.06▼$0.0650-Day Range$0.06▼$0.0652-Week Range$0.02▼$0.22Volume20,200 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get TearLab alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About TearLab Stock (OTCMKTS:TEAR)TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.Read More TEAR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TEAR Stock News HeadlinesJanuary 29, 2024 | finance.yahoo.comHarrow Announces New Appointments to its Board of DirectorsOctober 30, 2023 | benzinga.comSTRATA Skin Science Announces Leadership ChangeMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.July 12, 2023 | finance.yahoo.comOcular Therapeutix™ Announces Appointment of New Board MemberJanuary 15, 2023 | marketwatch.comOcular Allergy Diagnostic Systems Market Size 2023 with End-user Industries, Segments Covered in the ReportSeptember 9, 2022 | yahoo.comHousing Authority officials want more police help at East AcresSeptember 9, 2022 | yahoo.comLawrence schools on 'good footing' financiallySeptember 9, 2022 | nz.finance.yahoo.comPathway Makes Four Senior PromotionsMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.September 7, 2022 | apnews.comTearLab® Announces Corporate Name Change to Trukera™ Medical, Positions Company for Further Expansion in Corneal HealthJuly 20, 2022 | thestreet.comCramer's Top Stock Picks: CLDX OXY TEAR TSLAJune 8, 2022 | finance.yahoo.comNacuity Pharmaceuticals Strengthens Scientific Advisory Board with Appointment of Nancy Holekamp, M.D., and Richard L. Lindstrom, M.D. - Yahoo FinanceMay 23, 2022 | marketscreener.comAXIM BIOTECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.comMay 20, 2022 | marketscreener.comGreenbrook TMS : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS - Form 6-K - Marketscreener.comMay 12, 2022 | streetinsider.comXequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth - StreetInsider.comMay 11, 2022 | benzinga.comXequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth - B - BenzingaMay 11, 2022 | globenewswire.comXequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth - GlobeNewswireApril 12, 2022 | streetinsider.comForm DEF 14A LENSAR, Inc. For: May 25 - StreetInsider.comDecember 10, 2021 | finance.yahoo.comTearLab Corporation Announces Adam Szaronos as President and Chief Executive Officer, and Jim Mazzo as Executive Chairman of the BoardNovember 10, 2021 | markets.businessinsider.comTearLab Positioned For Growth With Jim Mazzo Joining Board of DirectorsNovember 9, 2021 | prnewswire.comTearLab Positioned For Growth With Jim Mazzo Joining Board of Directors - PRNewswireNovember 3, 2021 | seekingalpha.comAmgen, Inc. (AMGN) CEO Bob Bradway on Q3 2021 Results - Earnings Call Transcript - Seeking AlphaOctober 6, 2021 | streetinsider.comAXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board - StreetInsider.comOctober 5, 2021 | finance.yahoo.comAXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board - Yahoo FinanceOctober 4, 2021 | streetinsider.comOrasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan - StreetInsider.comSeptember 17, 2021 | prnewswire.comMellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans - PRNewswireSee More Headlines Receive TEAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TearLab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2019Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:TEAR Previous SymbolNASDAQ:TEAR CUSIPN/A CIK1299139 Webwww.tearlab.com Phone858-455-6006Fax858-812-0540Employees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Elias Vamvakas (Age 60)Exec. Chairman & Sec. Mr. Joseph S. Jensen (Age 47)CEO & Director Mr. Michael Marquez (Age 37)Chief Financial Officer Dr. Benjamin Sullivan Ph.D. (Age 43)Chief Scientific Officer Mr. Sam FakhouryVP of Quality, Compliance & Supply ChainKey CompetitorsAdynxxOTCMKTS:ADYXCalmare TherapeuticsOTCMKTS:CTTCDex LiquidatingOTCMKTS:DXTRQEndologixOTCMKTS:ELGXQHypertension DiagnosticsOTCMKTS:HDIIView All Competitors TEAR Stock Analysis - Frequently Asked Questions How have TEAR shares performed in 2024? TearLab's stock was trading at $0.0579 at the start of the year. Since then, TEAR stock has increased by 0.0% and is now trading at $0.0579. View the best growth stocks for 2024 here. How were TearLab's earnings last quarter? TearLab Co. (OTCMKTS:TEAR) issued its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.10) EPS for the quarter. The medical research company had revenue of $5.85 million for the quarter. When did TearLab's stock split? TearLab's stock reverse split on Friday, February 24th 2017. The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 23rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of TearLab own? Based on aggregate information from My MarketBeat watchlists, some companies that other TearLab investors own include Vertex Energy (VTNR), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Biocept (BIOC) and MEI Pharma (MEIP). How do I buy shares of TearLab? Shares of TEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TEAR) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TearLab Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
